{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:38:29Z","timestamp":1785307109037,"version":"3.55.0"},"reference-count":47,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2023,7,27]]},"abstract":"<jats:p>Baloxavir marboxil, an influenza virus polymerase acidic endonuclease inhibitor, represents a recently approved new class of influenza antivirals. Treatment-emergent resistance to baloxavir has been observed in clinical trials, and the potential spread of resistant variants could diminish baloxavir effectiveness.<\/jats:p>","DOI":"10.1128\/jvi.00154-23","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T14:42:25Z","timestamp":1689000145000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":31,"title":["Impact of Baloxavir Resistance-Associated Substitutions on Influenza Virus Growth and Drug Susceptibility"],"prefix":"10.1128","volume":"97","author":[{"given":"Brady T.","family":"Hickerson","sequence":"first","affiliation":[{"name":"Division of Biotechnology Review and Research II, Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana N.","family":"Petrovskaya","sequence":"additional","affiliation":[{"name":"Division of Biotechnology Review and Research III, Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Dickensheets","sequence":"additional","affiliation":[{"name":"Division of Biotechnology Review and Research II, Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-5276","authenticated-orcid":true,"given":"Raymond P.","family":"Donnelly","sequence":"additional","affiliation":[{"name":"Division of Biotechnology Review and Research II, Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Ince","sequence":"additional","affiliation":[{"name":"Division of Antivirals, Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8178-0472","authenticated-orcid":true,"given":"Natalia A.","family":"Ilyushina","sequence":"additional","affiliation":[{"name":"Division of Biotechnology Review and Research II, Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0002-y"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.03.046"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.05.031"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70121-4"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2021.04.002"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy874"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S105473"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-003-0262-6"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.294"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/v2102269"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716197"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz908"},{"key":"e_1_3_3_14_2","unstructured":"Center for Drug Evaluation and Research. 2020. Review and evaluation. NDA 210854. Xofluza (baloxavir marboxil). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/214410Orig1s000 %20210854Orig1s004 %20s010IntegratedR.pdf."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz418"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz472"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1916825117"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.02.007"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27890-4"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00009-22"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa164"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-022-05456-0"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2015.08.014"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02217-x"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2407.180028"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-014-0249-3"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009527"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104906"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.03026"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00430-18"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa527"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12821"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11091048"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010698"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac202028g"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2633"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1187816"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/ve\/vew014"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181999"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.15.8418-8425.2003"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308001101"},{"key":"e_1_3_3_42_2","unstructured":"Global Influenza Programme\u2014WHO. 2023. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: polymerase acidic (PA) inhibitor baloxavir. https:\/\/www.who.int\/teams\/global-influenza-programme\/laboratory-network\/quality-assurance\/antiviral-susceptibility-influenza\/polymerase-acidic-protein-inhibitor."},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.100133697"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s007050170002"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baw022"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.5.865"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.09.008"}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jvi.00154-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jvi.00154-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T13:02:59Z","timestamp":1690462979000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jvi.00154-23"}},"subtitle":[],"editor":[{"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,27]]}},"alternative-id":["10.1128\/jvi.00154-23"],"URL":"https:\/\/doi.org\/10.1128\/jvi.00154-23","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"2023-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00154-23"}}